Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study.

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

December 1, 2014

Primary Completion Date

September 18, 2017

Study Completion Date

September 18, 2017

Conditions
Renal TransplantAcute Antibody Mediated RejectionMild Immunologic Risk Factor
Interventions
DRUG

Nulojix (Belatacept)

Nulojix Administration will start the day of transplantation (day 1 and first dosing day);10 mg/kg : (day1, 5,14,28 ), Week 8 and 12 and then 5 mg/kg every 4 weeks until Month 12

Trial Locations (1)

94010

Henri Mondor Hospital, Créteil

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02738918 - Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study. | Biotech Hunter | Biotech Hunter